LAPTM4B Gene Polymorphism And Liver Cancer Susceptibility

Background and purpose:the development of liver cancer is an expression of process of variety genetic changes in the host cells. A new gene LAPTM4B was discovered and cloned by Professor Zhou Rouli, etc. who from Department of Cell Biology,School of Basic Medical Sciences,Peking University. LAPTM4B is associated with liver proliferation/differentiation, tumor grade and metastasis/ prognosis. LAPTM4B gene have two different alleles LAPTM4B *1 and LAPTM4B*2,*2 allele frequency in patients with hepatocellular carcinoma is higher than with normal control group, indicating*2 allele have higher risk of liver cancer. This paper further studies the frequency and characteristics of distribution of two alleles of LAPTM4B between liver cancer patients and control group patients. Furthermore, observes the correlation of LAPTM4B with pathological types, clinical TNM stage, and whether there is cross-correlation of LAPTM4B genotype with hepatitis B virus genotypes in HCC, as for accumulation of experimental evidence and theoretical basis of the LAPTM4B gene in the development of liver cancer molecular mechanisms.Materials and Methods:A case-control study, selected fasting venous blood samples of 86 HCC(hepatocellular carcinoma) patients and venous blood samples of 78 non-HCC control group patients from the October 2006 to October 2008 in the Hepatobiliary Surgery, PLA 302 hospital. Application of peripheral blood DNA extraction and application of PCR and electrophoresis detection of the two groups LAPTM4B genotype, statistics clinical pathological degree of differentiation, clinical stage and type of viral infec(?)ion, HBVDNA genotype, etc. Than, application of SPSS 13.0 statistical software, application pearson's×2 to analysis of liver cancer group and control group allele frequency, analysis the relevance of LAPTM4B genotype and HBVDNA genotype, defined P＜0.05 was statistically significant,95% was confidence interval.Results:1. LAPTM4B allele*1/*1,*1/*2 and*2/*2 distribution of frequencies were 31.4%, 59.3%,9.3% in liver cancer and 50.0%,38.5%,11.5% in the control group; genotype frequencies between the two groups were not significantly different (P= 0.1183). LAPTM4B gene*1 and*2 allele frequency distribution were 61.1%, 38.9% in the liver cancer group,67.9%,32.1% in the control group; two allele frequencies between the two groups were significant difference (P = 0.0039).2. LAPTM4B allele polymorphism in hepatocellular carcinoma patients is no significant correlation with pathological grade, clinical stage, (between the different pathological differentiation P-0.9892, between the different TNM stages P= 0.9987> 0.05).3. In different genotypes of HBVDNA and LAPTM4B, the ratio of*1/*1,*1/*2 and*2/*2 genotype in HBVDNA C of liver cancer group were 41.5%,48.8%, 9.7%, and in HBVDNA B of liver cancer were 30.0%,63.3%,6.7%; LAPTM4B genotype were no significant differences between HBVDNA C and B genotypes in HCC.(LAPTM4B in B, C-type HCC group x2=4.2745, P= 0.1180, in the B, C-type control group, x2= 0.5263, P= 0.7686).Conclusion:1. LAPTM4B allele *1/*1, *1/*2 and*2/*2 distribution in the liver cancer group and control group were not significant difference, LATPMB4 allele *1 and*2 distribution in the liver group and control group were significant difference,*2 allele have higher risk of liver cancer.2. LAPTM4B allele polymorphism in liver cancer patients was no significant correlation with the pathological differentiation, clinical stage.3. LAPTM4B genotype*1/*1,*1/*2 and*2/*2 were no significant differences between HBVDNA C and B genotypes in liver cancer susceptibility. There is not cross-correlation of two genotypes in HCC susceptibility. Each genotype may become to independent risk factor for liver cancer susceptibility.